Kai Kitamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kai Kitamura has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hiroaki Itoh
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
1 shared publication - Junhao Fu
The University of Tokyo
1 shared publication - Kaori Sakurai
Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Naka-cho, Koganei-shi, Tokyo 184-8588, Japan
1 shared publication - Koichi Kamiya
The University of Tokyo
1 shared publication - Masayuki Inoue
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
1 shared publication - Osamu Nureki
The University of Tokyo
1 shared publication
Latest Publications
- Open Access
- 14 July 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Photoaffinity Labeling Strategy Reveals Tetraspanin CD9 as a Transient Target of Anticancer Yaku'amide B
Innovative chemical strategies are needed to understand the molecular targets of natural products, especially when they engage with multiple targets via transient interactions. Yaku’amide B (1), an anticancer natural product, inhibits mitochondrial FoF1-ATP synthase with nanomolar affinity; however, this mechanism alone does not explain its unique activity. Here, we employed photoaffinity labeling (PAL), a powerful, key strategy, and discovered that tetraspanin CD9 is a transient cell surface target of 1 in cancer cells. Comprehensive analyses revealed that 1 binds to the cyto-plasmic N-terminal region of CD9 with micromolar affinity, thereby accelerating its cellular entry, inducing CD9 de-pletion via lysosomal proteolysis and inhibiting cancer cell migration. Thus, 1 represents the first natural product that binds to and promotes the degradation of CD9. This study underscores the versatility of applying the PAL strategy for mechanistic studies and establishes 1 as a novel molecular platform for targeting CD9-mediated cellular pathways.
- 14 July 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessPhotoaffinity Labeling Strategy Reveals Tetraspanin CD9 as a Transient Target of Anticancer Yaku'amide B
Innovative chemical strategies are needed to understand the molecular targets of natural products, especially when they engage with multiple targets via transient interactions. Yaku’amide B (1), an anticancer natural product, inhibits mitochondrial FoF1-ATP synthase with nanomolar affinity; however, this mechanism alone does not explain its unique activity. Here, we employed photoaffinity labeling (PAL), a powerful, key strategy, and discovered that tetraspanin CD9 is a transient cell surface target of 1 in cancer cells. Comprehensive analyses revealed that 1 binds to the cyto-plasmic N-terminal region of CD9 with micromolar affinity, thereby accelerating its cellular entry, inducing CD9 de-pletion via lysosomal proteolysis and inhibiting cancer cell migration. Thus, 1 represents the first natural product that binds to and promotes the degradation of CD9. This study underscores the versatility of applying the PAL strategy for mechanistic studies and establishes 1 as a novel molecular platform for targeting CD9-mediated cellular pathways.